Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Xlife Sciences AG
XLSXlife Sciences AG focuses on the development and commercialization of technologies in the life sciences sector. The company's project consists of technology platforms that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also engages in developing mono-and bispecific anti-tumor antibodies for the treatment of life-threatening diseases; researching, developing, and manufacturing chemical and active pharmaceutical ingredients for human and veterinary medicines; and early identification kidney diseases. Xlife Sciences AG also focuses on functional screening of antibodies by microfluidics-based technologies; and offers Neuromex, a screening instrument for the early-stage detection of neurodegenerative diseases. Xlife Sciences AG was founded in 2019 and is based in Zurich, Switzerland. Address: Talacker 35, Zurich, Switzerland, 8001
Analytics
Objectif de Cours de WallStreet
61.35 CHFRatio C/B
7.67Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés XLS
Analyse des dividendes XLS
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes XLS
Valorisation des titres XLS
financières XLS
Résultats | 2019 | Dynamique |